Optimized Alectinib Dose Regimen for Treatment of Patients with ALK-Positive Non-Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence.
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
5
References
2
Citations
NaN
KQI